BACKGROUND: A standardized protocol is used to administer recombinant human thyrotropin (rhTSH) in preparation for diagnostic studies and treatment in patients with thyroid cancer. The expectation is that serum TSH concentrations will peak on the day after the second injection and will be sufficiently elevated to stimulate uptake of radioiodine. We wished to test the hypothesis that TSH concentrations achieved after rhTSH injection are influenced by age. METHODS: Patients with thyroid cancer undergoing diagnostic radioiodine scanning were identified by chart review. Serum TSH concentrations were documented 24 and 72 hours after two rhTSH injections (days 3 and 5, respectively). Responses were subdivided into four ascending patient age groups: <35, 35-49, 50-64, and >64 years. TSH concentrations after rhTSH administration were documented according to patient age. RESULTS: There was a significant correlation between the serum TSH concentrations at both days 3 and 5 and patient age (p < 0.0001). None of the other factors examined (gender, menopausal status, weight, body mass index, baseline TSH, serum creatinine, and estimated glomerular filtration rate) were significant in multivariate analyses. The mean TSH concentration on day 3 increased significantly when patients were divided into the aforementioned groups of ascending age (96, 107, 142, and 196 mIU/L, p < 0.0001). Day 5 concentrations increased in a similar manner. CONCLUSIONS: Both days 3 and 5 TSH concentrations were higher in older individuals after rhTSH administration. This finding did not appear to be related to body weight, body mass index, or glomerular filtration rate in a simple manner. The TSH concentration achieved may be a result of complex interactions between distribution within fat and muscle body compartments, hepatic function, and renal function. Prospective studies could examine whether the magnitude of the TSH elevation after rhTSH administration affects diagnostic or therapeutic efficacy.
BACKGROUND: A standardized protocol is used to administer recombinant human thyrotropin (rhTSH) in preparation for diagnostic studies and treatment in patients with thyroid cancer. The expectation is that serum TSH concentrations will peak on the day after the second injection and will be sufficiently elevated to stimulate uptake of radioiodine. We wished to test the hypothesis that TSH concentrations achieved after rhTSH injection are influenced by age. METHODS:Patients with thyroid cancer undergoing diagnostic radioiodine scanning were identified by chart review. Serum TSH concentrations were documented 24 and 72 hours after two rhTSH injections (days 3 and 5, respectively). Responses were subdivided into four ascending patient age groups: <35, 35-49, 50-64, and >64 years. TSH concentrations after rhTSH administration were documented according to patient age. RESULTS: There was a significant correlation between the serum TSH concentrations at both days 3 and 5 and patient age (p < 0.0001). None of the other factors examined (gender, menopausal status, weight, body mass index, baseline TSH, serum creatinine, and estimated glomerular filtration rate) were significant in multivariate analyses. The mean TSH concentration on day 3 increased significantly when patients were divided into the aforementioned groups of ascending age (96, 107, 142, and 196 mIU/L, p < 0.0001). Day 5 concentrations increased in a similar manner. CONCLUSIONS: Both days 3 and 5 TSH concentrations were higher in older individuals after rhTSH administration. This finding did not appear to be related to body weight, body mass index, or glomerular filtration rate in a simple manner. The TSH concentration achieved may be a result of complex interactions between distribution within fat and muscle body compartments, hepatic function, and renal function. Prospective studies could examine whether the magnitude of the TSH elevation after rhTSH administration affects diagnostic or therapeutic efficacy.
Authors: P W Ladenson; L E Braverman; E L Mazzaferri; F Brucker-Davis; D S Cooper; J R Garber; F E Wondisford; T F Davies; L J DeGroot; G H Daniels; D S Ross; B D Weintraub Journal: N Engl J Med Date: 1997-09-25 Impact factor: 91.245
Authors: S S Koong; J C Reynolds; E G Movius; A M Keenan; K B Ain; M C Lakshmanan; J Robbins Journal: J Clin Endocrinol Metab Date: 1999-03 Impact factor: 5.958
Authors: Markus Luster; Francesco Lippi; Barbara Jarzab; Petros Perros; Michael Lassmann; Christoph Reiners; Furio Pacini Journal: Endocr Relat Cancer Date: 2005-03 Impact factor: 5.678
Authors: Maurice J H M Pluijmen; Carmen Eustatia-Rutten; Bernard M Goslings; Marcel P Stokkel; Alberto M Pereira Arias; Michaela Diamant; Johannes A Romijn; Jan W A Smit Journal: Clin Endocrinol (Oxf) Date: 2003-04 Impact factor: 3.478
Authors: H R Maxon; S R Thomas; V S Hertzberg; J G Kereiakes; I W Chen; M I Sperling; E L Saenger Journal: N Engl J Med Date: 1983-10-20 Impact factor: 91.245
Authors: C A Meier; L E Braverman; S A Ebner; I Veronikis; G H Daniels; D S Ross; D J Deraska; T F Davies; M Valentine; L J DeGroot Journal: J Clin Endocrinol Metab Date: 1994-01 Impact factor: 5.958
Authors: Agnese Barnabei; Lidia Strigari; Agnese Persichetti; Roberto Baldelli; Laura Rizza; Claudia Annoscia; Rosa Lauretta; Giovanni Cigliana; Maddalena Barba; Aurora De Leo; Marialuisa Appetecchia; Francesco Torino Journal: Front Endocrinol (Lausanne) Date: 2018-02-15 Impact factor: 5.555
Authors: Ana Zutinic; Hanno Pijl; Bart E Ballieux; Ferdinand Roelfsema; Rudi G J Westendorp; Gerard J Blauw; Diana van Heemst Journal: J Clin Endocrinol Metab Date: 2020-07-01 Impact factor: 5.958